Padcev® (enfortumab vedotin-ejfv) and keytruda® (pembrolizumab) significantly improve overall survival and progression-free survival in patients with previously untreated advanced bladder cancer in pivotal phase 3 ev-302 trial

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq: sgen) and astellas pharma inc. (tse:4503) today announced positive topline results from the phase 3 ev-302 clinical trial (also known as keynote-a39) for padcev® (enfortumab vedotin-ejfv) in combination with keytruda® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/muc), a form of bladder cancer that has spread to surrounding organs or muscles, or other pa.
SGEN Ratings Summary
SGEN Quant Ranking